Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte–Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and ThrombophiliaHypothesis Published on 2021-07-302022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] ACE2 adaptive affected Anemia angiotensin-converting enzyme 2 Angiotensin-converting enzyme 2 (ACE2) byproduct CD34 CD34+ hematopoietic stem cell (HSCs) Cell cell line cells cellular component Course COVID COVID-19 COVID-19 patient develop differentiation disease entry pathway Ex vivo hematopoietic Hematopoietic stem cell humoral immune cells Infection infections Inflammation Multiple Occurrence Particle Platelets progenitor protein translation RBC Replication risk RNA SARS-CoV-2 STEM target the disease the spike protein thrombocytopenia Thrombophilia thrombosis thrombotic event tissue vaccinated individuals Viral RNA virus Whole blood [DOI] 10.3390/microorganisms9081632 PMC 바로가기 [Article Type] Hypothesis
Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case SeriesNeurology Published on 2021-07-302022-11-01 Journal: Frontiers in Neurology [Category] COVID-19, [키워드] Adenovirus Autopsy causing cerebral Cerebral venous thrombosis ChAdOx1 ChAdOx1 nCoV-19 characteristic Clinical course Clinicians Cluster Combination Complication COVID-19 COVID-19 vaccination COVID-19 vaccine AstraZeneca Fatality rate fibrin clot FIVE form hallmark healthy hemorrhage Hemorrhagic high mortality rate induced Infarction Inflammation Intracerebral hemorrhage leukocyte manifestation membranes outcome patients presenting progression of disease resulting SARS-CoV-2 virus Sery sinus vein thrombosis syndrome Thrombocytes thrombocytopenia Thrombus treat Treatment Vaccine venous Venous thrombosis [DOI] 10.3389/fneur.2021.721146 PMC 바로가기 [Article Type] Neurology
Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic ThrombocytopeniaArticle Published on 2021-07-262023-06-15 Journal: Stroke [Category] MERS, SARS, [키워드] Cerebral venous thrombosis COVID-19 platelet factor 4 thrombocytopenia Vaccine [DOI] 10.1161/STROKEAHA.121.035613 PMC 바로가기
Vaccinations and Autoimmune DiseasesReview Published on 2021-07-222022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adverse event Adverse reaction associations Autoimmune diseases Autoimmunity caused characterized correlation demonstrated disorder dysregulation effective Epidemiological study explain flu vaccine Guillain-Barré syndrome heterogeneous group Hypothesis immune system immunization measure mechanism MMR occur occurred pandemic public health risk Safe SARS-CoV2 SARS-CoV2 vaccines Support syndrome Systemic autoimmune diseases the vaccine thrombocytopenia triggering vaccination Vaccine vaccine-induced immune thrombotic thrombocytopenia Vaccines [DOI] 10.3390/vaccines9080815 PMC 바로가기 [Article Type] Review
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?Commentary Published on 2021-07-212022-10-29 Journal: Infection [Category] COVID-19, MERS, SARS, [키워드] Adenovirus Vector cerebral COVID-19 PF4 antibody risk SARS-CoV-2 vaccination thrombocytopenia thrombosis Venous thrombosis [DOI] 10.1007/s15010-021-01658-x PMC 바로가기 [Article Type] Commentary
SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysisArticle Published on 2021-07-212023-07-02 Journal: American journal of obstetrics and gynecology [Category] SARS, [키워드] coronavirus COVID-19 eclampsia HELLP syndrome hepatic damage hypertension hypertensive disorders of pregnancy liver enzymes Maternal morbidity preeclampsia with severe features preeclampsia without severe features Proteinuria thrombocytopenia viral infection [DOI] 10.1016/j.ajog.2021.07.009 PMC 바로가기
Thyroid Storm-Induced Acute Liver Dysfunction and Disseminated Intravascular CoagulationArticle Published on 2021-07-202023-08-30 Journal: Cureus [Category] E형 간염, [키워드] Disseminated intravascular coagulation Graves disease Hepatitis thrombocytopenia thyrotoxicosis [DOI] 10.7759/cureus.16504 PMC 바로가기
A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trialSARS Cov-2 감염으로 입원한 환자에서 아스피린, 아토르바스타틴, 니코란딜을 사용한 삼중 요법의 효능과 안전성을 평가하기 위한 무작위 공개 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-07-152022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 ACHE Acute coronary syndrome Acute kidney injury acute renal failure adequate hydration adjuvant therapy Admission allergy ALT/AST Altered mental status Anti-inflammatory anticoagulation antipyretics Antithrombotic approved ARDS Aspirin AST/ALT atorvastatin bleeding Blinding block randomization Breastfeeding brown urine change characterized clinical clinical feature Clinical features Coagulopathy college Combination comorbid condition comorbid conditions comparator conducted control group coronary syndrome Corticosteroid Corticosteroids cough COVID-19 CPK creatine creatine kinase creatinine CRP current therapy Dexamethasone dissemination dose drug dysfunction Dyspnoea dysregulation effective Efficacy and safety element Endothelial dysfunction enrolled ethical committee evaluate excluded ferritin Fever followed by greater heparin hepatotoxicity Hospital admission hospital discharge Hospital mortality Hospital stay hospitalised patient Hospitalised patients hyperbilirubinemia hypoxia ICMR IEC immune dysregulation immunomodulatory impaired consciousness in-hospital mortality India Inflammation Inflammatory marker inflammatory markers Intervention intervention group intolerance intravenous Intravenous remdesivir invasive limit liver low molecular weight low molecular weight heparin management marker mechanical ventilation medication medications moderate muscle ache myalgia Myoglobin Myopathy myositis national guidelines Nicorandil Non-invasive number objective once daily Open-label open-label trial outcome oxygen Oxygen requirement oxygen support participant pathophysiologic pathophysiology Patient Platelet Platelet count Pneumonia positive Pregnancy Primary outcome progression protocol raised Rajendra Prasad Randomised control trial randomization randomize Randomized Randomized controlled trial randomly divided receive recruitment reducing mortality Registered registry Remdesivir renal failure reported respiratory rate rhabdomyolysis room air RT-PCR safety endpoint safety endpoints Sample size SARS-CoV-2 infected patient SARS-COV-2 infection Schematic screened Secondary outcomes Sepsis serum serum markers severe disease Shock significant interaction SpO2 Standard Standard of care starting dose statin statins Study design Study protocol substrates supplementary material Symptom Symptomatic treatment Tablet therapeutic therapeutic agent therapy thrombocytopenia Treatment Trial Trial registration two-arm parallel ULN Urine weakness website [DOI] 10.1186/s13063-021-05361-y PMC 바로가기 [Article Type] Letter
COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?Covid-19 백신 및 혈전증-로드 블록 또는 막 다른 거리?Review Published on 2021-07-132022-09-10 Journal: Biomolecules [Category] SARS, 변종, 유전자 메커니즘, [키워드] Ad26 Ad26.COV2.S addition Adenovirus adenovirus-based adverse effect antibodies approved BNT162b2 cause causes CD147 CD46 cellular ChAdOx1 ChAdOx1 nCoV-19 chronic smokers coronavirus coronavirus disease coronavirus disease-2019 COV2.S COVID-19 elicited EMA European Medicines Agency event Frequency Genetic groups heparan sulfate immune immunological mechanism in some incidence individual Interaction low frequency mRNA-based vaccines Platelet platelet factor 4 Proteoglycan recent receptor receptors reducing reported risk SARS-CoV-2 SARS-CoV-2 spike protein Smokers Spike protein splice sulfate the spike protein thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenia vaccination vaccine administration Vaccines variant Viral viral disease Viral diseases Viral vector viral vectors [DOI] 10.3390/biom11071020 PMC 바로가기 [Article Type] Review
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 EraOncology Published on 2021-07-082022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] Administered Affect Anemia approved Blood Cell Chemotherapy clinical development COVID-19 COVID-19 pandemic decrease dose growth factor Health health systems Hospitalization hospitalizations Improving incidence inhibitor Intervention intravenous less lung cancer maintain management myeloprotection myelosuppression neutropenia novel option Patient patients patients receiving placebo patients treated Physicians placebo-controlled clinical study progenitor cell Quality of life receiving recommendation reduced reducing regimen risk of infection Side effect significantly Standard-of-care supportive care thrombocytopenia Treatment [DOI] 10.3389/fonc.2021.697908 PMC 바로가기 [Article Type] Oncology